Novel Macrocyclic Compounds Targeting STING for Autoimmune Diseases Treatment
This patent demonstrates a series of macrocycle-based compounds that antagonize stimulator of interferon genes (STING), a key role in the innate immune response implicated in autoimmune diseases. These compounds, along with their pharmaceutically acceptable salt thereof, are intended for the treatment of autoimmune related diseases driven by STING-mediated pathways.
Authors
- Steven H. Liang (ORCID: https://orcid.org/0000-0003-1413-6315)
- Yanwei Jiang
Institutions
- Georgia Institute of Technology (US)
- Emory University (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2026-04-22
- DOI
- https://doi.org/10.1021/acsmedchemlett.6c00191
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00